NextBio

Help
Description: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Drug Type: Small Molecule; Approved
Pharmacology: Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.
Mechanism of Action: Carmustine causes cross-links in DNA and RNA, leading to the inhibition of DNA synthesis, RNA production and RNA translation (protein synthesis). Carmustine also binds to and modifies (carbamoylates) glutathione reductase. This leads to cell death.
Indication: For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
Half Life: 15-30 minutes
View Complete Description



Data Correlations | 2 studies

Help for Data Correlations View All
Genes category icon Genes
Score Help
GSR 100 100
Mbl1 100 100
RPL18 96 96
STAC3 92 92
TARBP2 90 90
C1orf210 87 87
View Top Genes
Biogroups category icon Biogroups
Score Help
Free Radical Induced Apoptosis 100 100
T-cell Receptor and CD3 Complex 97 97
Ras Pathway 95 95
Phospholipids As Signalling Interme… 95 95
IGF-1 mTOR Pathway 95 95
PTDINS Pathway 94 94
View Top Biogroups

Individual Studies

  • Drug target sets for approved compounds

    Homo sapiens Homo sapiens | Therapeutic   Therapeutic

    The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

    Authors: David S Wishart, Craig Knox, An Chi Guo et al.

    Organization: Department of Computing Science, Univers…

  • Liver Pharmacology and Xenobiotic Response Repertoire

    Rattus norvegicus Rattus norvegicus | RNA Expression   RNA Expression

    A definition of RNA expression changes that correlate with liver response programs and an understanding of the similarities and differences in responses to different classes of chemicals would aid in new chemical or drug characterization and add to our understanding of liver biology.

    Authors: Natsoulis G, Pearson CI, Gollub J et al.

    Organization: Iconix Biosciences 325 E. Middlefield Rd…
View All Individual Studies

Associated Researchers

Help for Associated Researchers

Thought leaders and organizations working on research involving bcnu.

View All Author iconAuthors
  • Henry Brem
  • P Amistà
  • Lili Liu
  • Brian D Ross
  • Alessandro Olivi
View All Clinical trial sponsors icon Clinical Trials Sponsors
  • Duke University
  • North Central Cancer Treatment Group
  • Stanford University
  • Ireland Cancer Center
  • Case Comprehensive Cancer Center
View All Affiliations icon Organizations
  • Duke University Medical Center
  • Johns Hopkins School of Medicine
  • Case Western Reserve University
  • Azienda Ospedale-Università
  • University of Iowa

Clinical Trials | 113 trials

Help for Clinical Trials View All

News | 1 story

Help for News View All

Community

Help for Community
NextBio Users

  • No NextBio users were found for “bcnu”.
    Complete your user profile with your interests, if you want others to find you within the NextBio community.

NextBio Groups

  • No NextBio groups were found for “bcnu”.
    Be the first to start a group and share your interests with others within the NextBio community.

© 2010 NextBio